Dihexa (also known in research literature as PNB-0408) from Super Human Peptides UK is a highly advanced, synthetic small-molecule peptide variant derived from Angiotensin IV. In laboratory research, Dihexa serves as a groundbreaking model for profound synaptogenesis and cognitive restoration. Unlike traditional nootropics that merely increase neurotransmitter levels, Dihexa is studied for its ability to physically rebuild the brain's structural network.
Researchers utilize it because it specifically binds to hepatocyte growth factor (HGF) and activates the c-Met receptor cascade—a pathway critical for neuronal survival, cellular repair, and new synapse formation. Produced under GMP-compliant conditions and verified for 99% purity or higher, Dihexa is an elite tool for advanced preclinical research into Alzheimer's disease, traumatic brain injury (TBI), and profound neuro-regeneration.
- —HGF/c-Met Activator: Potently binds to Hepatocyte Growth Factor to trigger the c-Met receptor cascade, signaling profound cellular repair.
- —Extreme Synaptogenesis: Demonstrated in laboratory models to be orders of magnitude more potent than Brain-Derived Neurotrophic Factor (BDNF) at creating new synaptic connections.
- —BBB Permeability: Specifically engineered to be highly lipophilic, ensuring excellent penetration across the blood-brain barrier.
- —Angiotensin IV Derivative: Synthetically modified from AngIV to possess a significantly extended half-life and extreme metabolic stability.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Documentation: Full Certificate of Analysis (COA) included with every batch.
- —Dendritic Spine Formation: Studying the rapid, physical outgrowth of new dendritic spines on cortical neurons, physically expanding the brain's communication network. Alzheimer's and
- —Dementia Models: Preclinical investigation into the reversal of cognitive deficits and severe memory loss in neurodegenerative states
- —Traumatic Brain Injury (TBI): Researching the structural repair and neuro-protection of the brain following severe concussive impact or ischemic damage.
- —Motor Function Restoration: Evaluating the improvement of fine motor skills and spatial awareness in chemically induced Parkinsonian animal models.
- —HGF/c-Met Pathway Mapping: Measuring the intracellular signaling kinetics triggered by HGF dimerization and subsequent c-Met phosphorylation.
Dihexa was developed by researchers at Washington State University, led by Dr. Joseph Harding and Dr. Jay Wright, who were searching for a highly stable Angiotensin IV analogue capable of crossing the blood-brain barrier to treat cognitive decline.
In their landmark laboratory studies, the researchers discovered that Dihexa exceeded all expectations. In preclinical assays measuring the formation of new synaptic connections, Dihexa was found to be over ten million times more potent than BDNF, the brain's natural growth factor. Animal models suffering from severe scopolamine-induced amnesia (mimicking Alzheimer's pathology) exhibited a total restoration of spatial memory and learning capabilities following administration.
Because it physically rebuilds damaged neural architecture rather than just temporarily masking symptoms, it is considered one of the most powerful neuro-regenerative compounds ever synthesized.
- 1.Harding, J.W. et al., "The development of angiotensin IV-based cognitive enhancing and neuroprotective agents," Frontiers in Systems Neuroscience, 2012.
- 2.McCoy, A.T. et al., "Evaluation of the cognitive-enhancing and neuroprotective properties of Dihexa," Journal of Pharmacology and Experimental Therapeutics, 2013.
- 3.Benoist, C.C. et al., "The pro-cognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system," Journal of Pharmacology and Experimental Therapeutics, 2014.
- 4.Wright, J.W. et al., "The angiotensin IV system: potential therapeutic targets for Alzheimer's disease," Current Alzheimer Research, 2015.
